tissue plasminogen activator
DrugRecombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
NCT Number: NCT03335839
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
University of Calgary - Foothills Medical Centre, Calgary, Alberta, Canada
STRIVE is a prospective, 3-arm, parallel group, blinded, randomized controlled trial evaluating the efficacy of a novel approach to prevent and treat microvascular obstruction thereby reducing major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
Placebo
Time frame: 30 days post-randomization
The primary efficacy variable is the binary composite outcome with the following components:
Time frame: 30 minutes post-PCI
Time frame: Immediately following PCI
Time frame: Immediately following PCI
Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)).
Time frame: Immediately following PCI
Post-procedural distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI.
Time frame: 30 minutes post-PCI
Failure to achieve ≥50% ST-segment resolution of the summed absolute ST-segment deviations across associated and reciprocal leads at 30 minutes post-PCI.
Time frame: 30 days post-randomization
Time to the first occurrence of MACE (composite of cardiovascular death, myocardial re-infarction, cardiogenic shock or new onset heart failure) over the duration of 30 days follow-up.
Time frame: 30 days post-randomization
Clinically overt, bleeding with at least one of the following criteria:
Time frame: 30 days post-randomization
Clinically overt, bleeding with at least one of the following criteria:
Time frame: 30 minutes post-PCI
Failure to achieve ≥ 50% resolution of the ST-segment value (worst lead) at 30 minutes post-PCI
Time frame: 30 days post-randomization
The composite of cardiovascular or non-cardiovascular death
Time frame: Immediately following PCI
Continuous measure of TIMI frame count as reported by Angiographic Core Lab.
Time frame: Immediately following PCI
Full perfusion of the infarct vessel with normal flow.
Time frame: 30 days post-randomization
All deaths with a CV or unknown cause will be classified as CV. Only deaths due to a documented non-CV cause will be classified as non-CV.
At least one of the following:
Population Health Research Institute
Other
Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction
Acronym: STRIVE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03445728
Cardiovascular Diseases, Heart Diseases
Beijing, China
View Trial DetailsNCT03925493
Cardiovascular Diseases, Coronary Artery Bypass Graft
Springfield, Massachusetts, United States
View Trial DetailsNCT02772133
Cardiovascular Diseases, Heart Diseases
Jinan, Shandong, China
View Trial DetailsNCT01235351
Cardiovascular Diseases, Heart Diseases
Boston, Massachusetts, United States
View Trial Details